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Abstract
Sequential injection analysis (SIA) technique and chemometric optimization were employed, for the first time, to develop a
new method for the assay of diltiazem in pharmaceutical formulations. The method was based on the spectrophotometric detection of permanganate reduction by diltiazem in acidic media at 526 nm. The 23 full factorial design and response surface plot were
adopted to optimize permanganate concentration, acid concentration and flow rate. The method was validated as per the International Union of Pure and Applied Chemistry (IUPAC) guidelines. Relatively, wide Beer’s law limit (10-180 mg/L) with satisfactory
linearity (correlation coefficient = 0.9996) and recovery (95.4-98.1%) were obtained. The method also recorded good repeatability
(RSD = 1.19-1.64%, n = 10) and intermediate-precision (2.84%, n = 5, once per a day). The method is sensitive enough for determining diltiazem in pharmaceutical formulations with limits of detection (1.30 mg/L) and quantification (3.94 mg/L). The method is
rapid with sample frequency of 32 sample/h. The method was applied to real pharmaceutical samples and the results obtained were
realized by parallel analysis by another validated method. The method enjoys the potentials of SIA and chemometric optimization
with respect to good accuracy, precision, sensitivity and rapidity. The method is also inexpensive in terms of instrumentation as well
as the consumption of reagents and samples. Besides good safety for handling solutions, the SIA technique offers significant waste
minimization and manpower reduction to the proposed method. Therefore, the SIA method is suitable in pharmaceutical laboratory
for quality control purpose.
Key words: sequential injection analysis, chemometrics, diltiazem, pharmaceutical analysis

INTRODUCTION
In recent pharmaceutical analysis, there is an
increasing demand for rapid, instrumentally inexpensive and reagent/sample saving methods. In addition,
safety in handling reagents and sample as well as safety
to the environment are as important as other analytical
aspects. Flow injection (FI) techniques are well-suited
to fulfill the requirements of modern pharmaceutical
analysis. FI techniques are in continuous development
and up-to-date three generations were introduced. The
first generation is flow injection analysis (FIA). It was
introduced by Ruzicka and Hansen in 1975(1). In 1990,
Ruzicka and Marshall introduced sequential injection
analysis (SIA), as the second generation, with dramatic
* Author for correspondence. Tel. +966-3-5805361;
Fax: +966-3-5886437; E-mail address; fnassubaie@yahoo.com

modifications and developments(2). Thereafter, Ruzicka
et al. developed the third generation, i.e. bead injection
analysis (BIA), with special applications (3). In spite of
the advantages of SIA over FIA, the latter technique is
still most dominant. This may be attributed to the fact
that FIA is simpler and more familiar than SIA. However,
SIA enjoys outstanding features including full-automation, miniaturization and versatility. Publications demonstrating the principles and developments of SIA are available elsewhere (4-7).
Due to its useful potentials, SIA has received special
attention in pharmaceutical analysis for different purposes
including serial assays, drug dissolution testing and drug
screening. The applications of SIA to pharmaceuticals are
discussed in a number of informative publications(8-13).
On the other hand, developing new analytical methods
requires critical optimization of experimental conditions,
which potentially control analysis. Univariate, as the most
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popular optimization approach, optimizes experimental
conditions one-by-one by varying levels of one condition
while keeping others constant at unspecified levels.
However, the chemometrics approach, which is based on
multivariate analysis, is more powerful than the univariate
approach. Chemometrics gains the highest efficiency of
analytical methods in the shortest way. This feature saves
time, minimizes effort as well as reduces the consumption of
reagents and samples. Chemometrics performs optimization
throughout the following means : (i) Examining the main
and the interaction effects of experimental conditions
on the efficiency of analytical methods; (ii) Optimizing
experimental conditions considering their interactions;
(iii) Developing simultaneously more than one analytical
aspect; (iv) Reducing a large amount of data that can be
easily interpreted; (v) Testing the ruggedness. More details
on the principles and applications of chemometrics are
available elsewhere(14). Successful applications of exploiting
chemometrics for optimizing SIA methods were reported
elsewhere(15-23).
Diltiazem hydrochloride, which belongs to benzothiazepine class, is chemically named 3-acetyloxy-5-(2(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)1,5-benzothiazepin-4(5H)one monohydrochloride (Figure
1). Diltiazem is a calcium channel blocker widely used
as an anti-anginal and anti-hypertensive agent. Due to
its popularity, several methods for the assay of diltiazem have been reported. The United States Pharmacopoeia (USP) specifies a non-aqueous potentiometric
titration method in pure and tablet form(24). The British
Pharmacopoeia also specifies potentiometric titration
method for bulk form while no method for pharmaceutical formulations is described(27). In addition, several
spectrophotometric(26-37), high performance liquid chromatographic(38), micellar liquid chromatographic(39,40)
and high-performance thin-layer chromatographic(41,42)
methods were reported.
The current study deals with utilizing SIA technique with chemometric optimization approach for
developing a new assay method for diltiazem in pharmaceutical formulations. The method is based on the oxidation of the drug by permanganate in acidic media. The
reduction of permanganate was spectrophotometrically
detected. Permanganate, as a superior oxidizing agent
with high absorptivity, was found to be selective in highly
controlled experimental conditions(19,43,44).

MATERIALS AND METHODS
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Figure 1. Chemical structure of diltiazem hydrochloride
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Figure 2. Schematic diagram of a SIA manifold constructed for
diltiazem assay

USA). It is composed of a syringe pump (SP), multiposition valve (MPV), holding coil (HC) and Z-flow
cell (Z) as well as pump tubing and personal computer
(PC). The SP includes 24,000 increments with a highresolution stepper motor, which drives the piston at
rates from 1.5 s to 10.0 min per stroke. The SP is > 99%
accuracy at full stroke. The syringe has a volume of 2.5
mL. The MPV is chemically inert and has eight ports
with a standard pressure of 250 psi (gas)/600 psi (liquid)
and zero dead volume. The Z is 10 mm path-length
Plexiglass compatible with fiber optic connectors. Pump
tubing of 0.03” I.D. Teflon type supplied from Upchurch
Scientific, Inc. (Oak Harbor, WA, USA) was used to
connect SIA units and to make a HC (150 cm long).
The optical devices were composed of a radiation
source, spectrometer and fiber optic connectors. They
were fabricated by Ocean Optics (Dunedin, FL, USA).
The radiation source is an LS-1 Tungsten Halogen lamb
optimized for VIS-NIR (360 nm-2 μm wavelength range).
The detector is a USB2000 Spectrometer adapted to
200-1100 nm wavelength range. The fiber optic connectors
are 200 micron SubMiniature version A (SMA).

I. Instrumentation and Software Packages

II. Software Packages

The manifold used in this work is composed of a
SIA system combined with a miniaturized fiber optic
spectrometer. The components of the manifold are
diagrammed in Figure 2.
The SIA system is FIALab 3500 (Medina, WA,

FIALab® for Windows version 5.0 supplied from
FIAlab (Medina, WA, USA) was used for programming
and controlling SIA manifold. Spectrophotometric data
was collected and processed using OOIBase® Software version 2.0.1.2 supplied from Ocean Optic, Inc
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(Dunedin, FL, USA). SigmaPlot® for Windows version
9.01 supplied from Systat Software, Inc. (Point Richmond, CA, USA) was used for interpolating data and
constructing surface plots.
III. Chemicals and Reagents
All chemicals and reagents used in this study were
of analytical reagent grade. The quality of water was
distilledly deionized. Diltiazem hydrochloride as standard material was supplied from Sigma-Aldrich (Quımica
S.A., Spain). Potassium permanganate and sulfuric acid
were supplied from Fluka (Buchs, Switzerland). Some
inactive ingredients possibly found in tablet and capsule
formulations were a generous gift from Salah Factory
(Khartoum North, Sudan). Inactive ingredients included
sodium citrate, microcrystalline cellulose, magnesium
stearate, maize starch, titanium dioxide, carnauba wax,
propylene glycol, povidone and talc.
V. Pharmaceutical Samples
Adizem-SR® tablets (120 mg diltiazem) and AdizemXL (200 mg diltiazem) capsules manufactured by Napp
Pharmaceuticals Ltd. (Cambridge, UK) were examined
in the current study. Tildiem® tablets (60 mg diltiazem)
manufactured by Sanofi-aventis Ltd. (Surrey, UK) as
well as Dilzem-XL® capsules (180 mg diltiazem) manufactured by Cephalon Ltd. (Hertfordshire, UK) were also
examined.
®

VI. Preparation of Reagents and Standard Solutions
A stock standard solution of 1000 mg/L diltiazem
was prepared by dissolving an appropriate amount
directly in water. In addition, a stock standard solution
of 0.02 M potassium permanganate was prepared and
standardized weekly. Working standard solutions of diltiazem, permanganate and sulfuric acid were prepared by
dilution in an appropriate way.
IIIV. Preparation of Pharmaceutical Samples
Ten tablets were ground and 10 capsules were
refilled. An equivalent amount of 10 mg diltiazem
powders of tablets and capsules were accurately weighed.
The weights were extracted into 25 mL chloroform and
filtrate through Whatman® No. 42 filter paper. The filtrate
was evaporated under vacuum to dryness. The residue
was resuspended with distilled deionized water and transferred to a 100 mL volumetric flask and diluted to volume.
Three placebo samples were prepared including inactive ingredients in a concentration range of 20-100 mg/L
VII. SIA Procedure
As shown in figure 2, a single-channel SIA manifold

was constructed to perform on-line developing reaction
and spectrophotometric measurement. Port-1 in the MPV
was linked with the Z. Water was linked with both the
SP and port-2 in the MPV. Permanganate solution was
linked with port-3. Standards/samples were attached to
ports-3-8. A rapid protocol controlling the proposed SIA
procedure was programmed. It is briefly described as
follows.
i.
Following the practice of SIA, the syringe was
firstly filled with 1500 µL of water for propelling solutions.
ii. Each solution was loaded into the HC by aspiration using the SP. The excess of solutions was
dispensed to the waste.
iii. The syringe was filled again with 1500 µL of
water.
iv. 30 µL of each of sulfuric acid and permanganate solutions were sequentially aspirated into
the HC.
v. The solutions were mixed by reverse-flow of
10 µL at a flow rate of 30 µL/s.
vi. 50 µL of water, as a blank solution, was
injected into the HC and mixed.
vii. The mixture was dispensed through the Z at
the required flow rate. During flowing, the
maximum permanganate absorbance was
recorded at 570 nm.
viii. For standard/sample measurement, steps iii-vii
were repeated with replacing standard/sample
instead of blank.
ix. The response «R» of permanganate reduction
was calculated as the difference of absorbance
before and after adding standard/sample.

RESULTS AND DISCUSSION
I. Chemometric Optimization
Primarily, it has been found that diltiazem is
possibly oxidized by permanganate in sulfuric acidic
media. Spectrophotometric study showed that there was
no spectrum interference at 526 nm, a wavelength that
was set for detecting permanganate absorbance before
and after reduction. Suitable ranges of permanganate
concentration, acid concentration and flow rate were
examined for chemometric optimization. At permanganate concentration more than 5.0 × 10 -3 M, lower diltiazem concentration in samples may record insignificant
reduction of permanganate absorbance. On the other side,
permanganate concentration less than 5.0×10 -4 M may
narrow the Beer’s law limit. For sulfuric acid concentration, the range of 1.0 × 10 -2-1.0 × 10 -3 M recorded,
primarily, significant reduction of permanganate by
diltiazem. In general, higher sulfuric acid concentration
distorts the base line of the SIAgram and produces nonrepeatable spectrophotometric measurement (19,20,22,23,44).
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Table 1. 23 full factorial design matrix with experimental results (responses)
Experiment number

Permanganate concentration
(M)

Sulfuric acid concentration
(M)

Flow rate
(µL/s)

Response

1

5.0 × 10-4

1.0 × 10-3

10

0.136

2

5.0 × 10-4

1.0 × 10-3

40

0.172

3

5.0 × 10-4

1.0 × 10-2

10

0.108

4

-4

-2

40

0.160

-3

5.0 × 10

1.0 × 10

-3

5

5.0 × 10

1.0 × 10

10

0.255

6

5.0 × 10-3

1.0 × 10-3

40

0.297

7

5.0 × 10-3

1.0 × 10-2

10

0.222

8

-3

-2

40

0.264

5.0 × 10

1.0 × 10

0.28

0.28

0.24

0.24
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Figure 3. Response surface plot of permanganate concentration (M)
against acid concentration (M)

Figure 4. Response surface plot of permanganate concentration (M)
against flow rate (µL/s)

Regarding flow rate for spectrophotometric measurement, following the practice of SIA, a range of 10-40
µL/s is always suitable.
The 23 full factorial design was adopted in the
current study. The base 2 stands for the number of
experimental conditions levels. The power 3 stands
for the number of experimental conditions would be
optimized. A total of 8 experiments were carried out
using experimental conditions as illustrated in Table 1.
The results obtained are also introduced in Table 1.
The data in the adopted factorial design matrix
including response values was interpolated using values
(-1) and (+1) instead of the minimum and the maximum
values of experimental condition levels (7). Then, the
response surface was plotted and depicted in Figures 3-5.
Figure 3 shows a positive permanganate

concentration effect on response while a negative acid
concentration effect on response is recorded. Moreover,
the order of permanganate concentration effect is higher
than that of acid concentration effect. In general, high
permanganate concentration enhances the oxidation of
diltiazem. Negative acid concentration effect may be due
to relatively low acidity of diltiazem. On the other hand,
the trend of acid concentration effect on response, which
is negative (Figure 3), is similar to the trend of flow rate
effect (Figure 4). Negative effect of flow rate indicates
that the oxidation of diltiazem by permanganate is slow.
Therefore, the reaction could be enhanced by applying
low flow rate, which allows reaction to take place before
measurement. Figure 5 shows that the order of flow rate
effect on response is higher than that of acid concentration effect. In Figure 3, the semi-flat surface appeared
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in the corner of higher permanganate concentration
and lower acid concentration indicates that there is no
need to examine further levels beyond levels adopted in
the current study. The outputs of both Figures 4 and 5
strengthen this finding. On the other hand, Figures 4 and
5 also depict semi-flat surface with respect to flow rate.
Hence, a flow rate of 15 µL/s was examined and similar
response was recorded. Eventually, the finding of the
chemometric optimization is that 5.0×10 -3 M permanganate, 1.0×10 -2 M sulfuric acid and 15 µL/s flow rate were
set as the optimum levels.
II. Method Validation
Under the optimized experimental conditions, the
SIA method was validated based upon the International
Union of Pure and Applied Chemistry (IUPAC) guidelines (45) in terms of Beer’ law limit, recovery, repeatability, intermediate-precision and sample frequency as
well as limits of detection and quantification.
To examine the Beer’ law limit, a long series

0.21

of standard solutions of diltiazem (1-300 mg/L) was
subjected to the proposed SIA method. The method
was found to be linear in the range of 10-180 mg/L. The
weighed regression of the calibration equation obtained
was “R = 0.0025C + 0.0368”, where R is the response
(absorbance unit) and C is diltiazem concentration in
mg/L. The correlation coefficient obtained was 0.9996
indicating good linearity.
Three placebo samples were subjected to the SIA
method. Each sample was analyzed three times for diltiazem. No reduction of permanganate under the optimum
conditions was recorded indicating good selectivity of
the SIA method in the presence of excipients usually
found in tablet and capsule formulations.
The intermediate-precision was also examined by
replicating 5 experiments, each per day within one week.
The RSD was found to be 2.84% indicating also satisfactory intermediate-precision. Sample frequency of the
proposed method was calculated. The software controlling the SIA system counted 112.5 s for each experiment.
Therefore, sample frequency obtained was 32 sample/h,
which indicates fast analysis.
The limit of detection (LOD) was examined as the
concentration of solute resulting in a peak height three
times the baseline noise level while the limit of quantification (LOQ) was examined as the concentration of
solute resulting in a peak height ten times the baseline
noise level. The LOD and LOQ were 1.30 and 3.94 mg/L,
respectively.
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Figure 5. Response surface plot of acid concentration (M) against
flow rate (µL/s)

Pharmaceutical samples were subjected to the validated SIA method. The same tablet samples were also
subjected to the USP method while the same capsules
samples were subjected to a spectrophotometric method,
which was based on the formation of colored chloroform extractable ion-pair complex of the diltiazem with
bromothymol blue in acidic medium(32). In that method,
validation study was conducted and acceptable results
were obtained.
Samples were analyzed ten times. The repeatability
as RSD, mean recovery and t-test value were calculated.

Table 2. Results obtained by the SIA, USP and spectrophotometric methods for the assay of diltiazem in pharmaceutical formulations
SIA method

USP method

Spect.1 method

M.R.3 ± RSD(%)4

M.R.3 ± RSD(%)

M.R.3 ± RSD(%)

Tablets (60 mg)

96.5 ± 1.24

94.2 ± 2.70

-

2.08

Pharmaceutical sample

Formulation and content

Tildiem-SR®
Adizem-SR®

t2

Tablets (120 mg)

95.4 ± 1.37

95.7 ± 2.51

-

1.98

®

Capsules (180 mg)

98.1 ± 1.19

-

94.3 ± 3.41

2.31

®

Capsules (200 mg)

97.9 ± 1.64

-

94.0 ± 3.68

2.09

Dilzem XL

Adizem-XL

1: Spectrophotometric; 2: Student t-test values; 3 Mean recovery; 4: Relative standard deviation for 10 replicates
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The results obtained are introduced in Table 2. The
values of RSD and mean recovery indicate acceptable
accuracy and repeatability. The calculated t-test values
were found to be lower than that tabulated emphasizing
the reliability of the results obtained by the SIA method.

CONCLUSIONS
For the first time, a SIA method for diltiazem assay
in pharmaceutical formulations was developed. The
method enjoys the potentials of SIA with respect to automation and miniaturization. Comparing with previous
methods, the newly developed SIA method is inexpensive
with respect to instrumentation as well as reagent and
sample consumption. The method is also rapid, accurate
and repeatable as well as safe in handling reagents and
safe to the environment.

ACKNOWLEDGMENTS
The author would like to thank the financial support
from the Deanship of Scientific Research at King Faisal
University, Saudi Arabia, award # 7039. The author also
thanks the Department of Chemistry, College of Science,
King Faisal University for allowing him to conduct this
research.

RREFERENCES
1. Ruzicka, J. and Hansen, E. H. 1975. Flow injection
analysis: Part I. A new concept of fast continuous flow
analysis. Anal. Chim. Acta. 78: 145-157.
2. Ruzicka, J. and Marshall, G. D. 1990. Sequential injection: A new concept for chemical sensors, process
analysis and laboratory assays. Anal. Chim. Acta. 237:
329-343.
3. Ruzicka, J., Pollema, C. H. and Scudder, K. M. 1993.
Jet ring cell: A tool for flow injection spectroscopy and
microscopy on a renewable solid support. Anal. Chem.
65: 3566-3570.
4. Aldstadt, J. H., Olson, D. C., Wolcott, D. K., Marshal
G. D. and Steig, S. W. 2000. Flow and sequential injection analysis techniques in process analysis. In R. A.
Meyers, R. A. Meyers. Encyclopedia of Analytical
Chemistry. 15: Applications, Theory and Instrumentation. John Wiley & Sons Inc., Hoboken, NJ, USA.
5. Hansen, E. H. and Wang, J. 2004. The three generations of flow injection analysis. Anal. Lett. 37: 345-359.
6. Idris, A. M. An overview of the generations and recent
versions of flow injection techniques. Crit. Rev. Anal.
Chem. In press.
7. Solich, P., Sklenarova, H., Polasek, M. and Larlicek, R.
2001. Application of flow injection technique in pharmaceutical analysis. Part I: Spectrophotometric and

chemiluminescence detection. J. Flow Inject. Anal. 18:
1-13.
8. Solich, P., Sklenarova, H., Polasek, M. and Larlicek,
R. 2001. Application of flow injection technique in
pharmaceutical analysis. Part II: Other spectroscopic
methods and electroanalytical detection. J. Flow Inject.
Anal. 18: 118-132.
9. Evgenev, M. I. Garmonov, S. Yu. and Shakirova, L. Sh.
2001. Flow-injection analysis of pharmaceuticals,” J.
Anal. Chem. 56: 313-323.
10. Solich, P., Polasek, M., Klimundova, J. and Ruzicka, J.
2004. Sequential injection technique applied to pharmaceutical analysis. TrAC. 23: 116-126.
11. Pimenta, A. M., Montenegro, M. C. B. S. M., Araujo,
A. N. and Calatayud, J. M. 2006. Application of
sequential injection analysis to pharmaceutical analysis. J. Pharm. Biomed. Anal. 40: 16-34.
12. Mervartova, K., Polasek, M. and Calatayud, J. M.
2007. Recent applications of flow-injection and sequential-injection analysis techniques to chemiluminescence
determination of pharmaceuticals. J. Pharm. Biomed.
Anal. 45: 367-381.
13. Tzanavaras, P. D. and Themelis, D. G. 2007. Review of
recent applications of flow injection spectrophotometry
to pharmaceutical analysis. Anal. Chim. Acta. 588: 1-9.
14. Morgan, E. D. 1991. Chemometrics: Experimental
Design. ACOL, JohnWiley & Sons, London, UK.
15. Suliman, F. E. O. and Sultan, S. M. 1997. Sequential
injection method for the determination of oxprenolol in
pharmaceutical products using chemometric methods
of optimization. Microchem. J. 57: 320-327.
16. Sultan, S. M., Hassan, Y. A. M. and Ibrahim, K.
E. E. 1999. Sequential injection titrimetric analysis
of vitamin C in drug formulations using potassium
permanganate. Analyst 124: 917-921.
17. Sultan, S. M., Hassan, Y. A. M. and Ibrahim, K. E. E.
1999. Sequential injection spectrophotometric assay
of bromazepam complexed with iron(II) in hydrochloric acid with chemometric optimization. Talanta
50: 841-849.
18. Suliman, F. E. O., Al-Lawati, H. A. J., Al-Kindy, S. M.
Z., Nour, I. E. M. and Salama, S. B. 2003. A sequential
injection spectrophotometric method for the determination of penicillamine in pharmaceutical products by
complexation with iron(III) in acidic media. Talanta 61:
221-231.
19. Sultan, S. M., Idris, A. M. and Ibrahim, K. E. E. 2004.
Sequential injection spectrophotometric method for the
assay of paracetamol in drug formulations. J. Flow
Inject. Anal. 21: 19-24.
20. Idris, A. M., Assubaie, F. N. and Sultan, S. M. 2006.
Chemometric optimization of a SIA promethazine
hydrochloride assay method. Microchem. J. 83: 7-13.
21. Pasamontes, A. and Callao, Ma. P. 2006. Optimization by means of responses surface of an analytical
sequence using a sequential injection system. Talanta
68: 1617-1622.

414
Journal of Food and Drug Analysis, Vol. 17, No. 6, 2009

22. Idris, A. M., Assubaie, F. N. and Sultan, S. M. 2007.
Experimental design optimization of a sequential injection method for promazine assay in bulk and pharmaceutical formulations. J. Autom. Methods Manag.
Chem. 2007: 32470-32476.
23. Idris, A. M. 2007. On-line coupling of solid-phase
extraction, derivatization and spectrophotometry by
sequential injection analysis: application to trifluoperazine assay in human urine. J. Pharmacol. Toxicol.
Methods 56: 330-335.
24. United States Pharmacopoeia, E-copy on CD, Version
26 NF-21, 2003.
25. British Pharmacopoeia, E-copy on CD, Version 6.0,
2002.
26. Kamath, B. V. and Shivram, K. 1991. Extractive spectrophotometric method for the determination of diltiazem hydrochloride in its dosage forms. Indian Drugs.
29: 50-52.
27. Agrawal, Y. K. Shivramachandra, K. and Rao, B. E.
1992. Spectrophotometric methods for the determination of diltiazem in pharmaceutical preparations.
Indian J. Pharm. Sci. 54: 218-221.
28. Zivanov-Stakic, D., Agbaba, D., Vladimirov, S. and
Ciric., L. J. 1992. Spectrophotometric determination of
diltiazem in dosage forms. Farmaco. 47: 393-396.
29. Kamath, B. V., Shivram, K. and Shah, A. C. 1993.
Selective spectrophotometric determination of diltiazem hydrochloride in tablets. J. Pharm. Biomed. Anal.
11: 407-409.
30. Sastry, C. S. P., Sreedhar, K., Reddy, M. N. and
Sankar, D. G. 1995. Visible spectrophotometric
methods for the determination of diltiazem hydrochloride. Indian J. Pharm. Sci. 57: 170-172.
31. Sreedhar, K., Sastry, C. S. P., Reddy, M. N. and
Sankar, D. G. 1995. Extractive spectrophotometric
determinations of diltiazem hydrochloride. Indian
Drugs. 32: 90-92.
32. Rahman, N. and Hejaz-Azmi, S. N. 2000. Extractive spectrophotometric methods for determination of
diltiazem HCl in pharmaceutical formulations using
bromothymol blue, bromophenol blue and bromocresol
green. J. Pharm. Biomed. Anal. 24: 33-41.
33. Rahman, N. and HejazAzmi, S. N. 2000. Spectrophotometric determination of diltiazem hydrochloride with
sodium metavanadate. Microchem. J. 65: 39-43.
34. Ayad, M. M., Shalaby, A., Abdellatef, H. E. and Hosny,
M. M. 2003. New colorimetric methods for the determination of trazodone HCl, famotidine, and diltiazem
HCl in their pharmaceutical dosage forms. Anal.
Bioanal. Chem. 376: 710-714.

35. Pietras, R., Kowalczuk, D. and Hopkala, H. 2004.
Comparison of classical and derivative UV-spectrophotometric methods for the quantification of diltiazem
and mexiletine,” Acta Pol. Pharm. 61: 315-320.
36. El-Didamony, A. M. 2005. Indirect spectrophotometric
determination of diltiazem hydrochloride in pure form
and pharmaceutical formulations. Cent. Eur. J. Chem.
3: 520-536.
37. Leitao, J. M. M. and Esteves da Silvab, J. C. G. 2008.
Factorial analysis optimization of a diltiazem kinetic
spectrophotometric quantification method. Anal. Chim.
Acta. 609: 1-12.
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